Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO-B

425.800
+4.8001.14%
Volume:558.82K
Turnover:240.63M
Market Cap:99.29B
PE:-353.78
High:441.600
Open:420.800
Low:418.800
Close:421.000
52wk High:581.000
52wk Low:228.200
Shares:233.19M
HK Float Shares:162.77M
Volume Ratio:0.95
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.204
ROE:-9.34%
ROA:-4.26%
PB:18.01
PE(LYR):-353.78
PS:42.60

Loading ...

Assessing Kelun-Biotech (SEHK:6990) Valuation After NMPA IND Approval For Long Acting Autoimmune Antibody

Simply Wall St.
·
Mar 14

Sichuan Kelun-Biotech Hires Associate For Promotional Services of Drug

MT Newswires Live
·
Mar 11

SKB BIO-B (06990) Signs 2026 Ancillary Market Management Services Framework Agreement with Kelun Jiaxun

Stock News
·
Mar 10

BUZZ-Sichuan Kelun-Biotech jumps most in near 12 months on drug application

Reuters
·
Mar 10

Clinical Trial Approval for TSLP Bispecific Antibody Boosts SKB BIO-B and HBM HOLDINGS-B Shares

Stock News
·
Mar 10

Kelun-Biotech and Harbour Biomed Announce Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Atopic Dermatitis

THOMSON REUTERS
·
Mar 09

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says NMPA Approves IND Application For SKB575/HBM7575

Reuters
·
Mar 09

Sichuan Kelun-Biotech Secures Regulatory Approval to Begin Human Trials of Dermatology Drug

MT Newswires Live
·
Mar 09

Kelun-Biotech (06990.HK) Secures NMPA IND Green Light for Long-Acting Bispecific Antibody SKB575 Targeting Atopic Dermatitis

Bulletin Express
·
Mar 09

China NMPA approves Kelun-Biotech IND for SKB575 in atopic dermatitis

Reuters
·
Mar 09

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd - Nmpa Approves Ind Application for Skb575/Hbm7575

THOMSON REUTERS
·
Mar 09

SKB BIO-B (06990) Announces Monthly Equity Movements for February 2026

Bulletin Express
·
Mar 04

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s Valuation After The Crescent Biopharma Oncology Partnership

Simply Wall St.
·
Feb 28

BUZZ-Crescent Biopharma rises as global trial for new cancer drug starts

Reuters
·
Feb 19

SKB BIO-B Falls 3.33% Against Market Trend, Weighed by Sector Weakness and Divergent Institutional Views

Deep News
·
Feb 12

China International Capital Maintains Outperform Rating on SKB BIO-B (06990) with HK$550 Target Price

Stock News
·
Feb 11

Goldman Sachs: Mainland Healthcare Sector Returns to Hinge on Data and Earnings Visibility This Year, CDMO Firms Favored

Stock News
·
Feb 09

BRIEF-Sichuan Kelun-Biotech Biopharmaceutical Says Trop2 Adc Sacituzumab Tirumotecan Approved For Marketing For Fourth Indication By China's NMPA

Reuters
·
Feb 06

Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (Sac-TMT) Approved by Nmpa in Hr+/Her2- Breast Cancer

THOMSON REUTERS
·
Feb 06

Sichuan Kelun-Biotech (6990) Announces Fourth NMPA Approval of TROP2 ADC Sacituzumab Tirumotecan for Advanced HR+/HER2- Breast Cancer

Bulletin Express
·
Feb 06